Repeatability of Spectralis OCT Measurements of Macular Thickness and Volume in Diabetic Macular Edema
Repeatability of Spectralis OCT Measurements of Macular Thickness and Volume in Diabetic Macular Edema
复制标题
DOI：
10.1167/iovs.12-10895
复制
发表时间：
2012-11-01
影响因子：
4.4
通讯作者：
Patel, Praveen J.
中科院分区：
文献类型：
--
作者：
Comyn, Oliver;Heng, Ling Zhi;Patel, Praveen J.
目的.我们估计了光谱光学相干断层扫描（OCT）衍生的自动视网膜厚度和体积测量的重复性系数，在涉及中心的糖尿病黄斑水肿（DME）的受试者。共有50例连续患者的50只眼发生中心累及DME，在一次治疗中使用一台OCT设备（由两名经验丰富的操作员之一操作）进行了四次连续的“快速”体积扫描。计算Bland-Altman重复性系数（CR），用于9个糖尿病视网膜病变早期治疗研究（ETDRS）子视野中的自动视网膜厚度测量、中心点厚度和总黄斑体积。评估扫描的显著自动视网膜边界检测误差，并修订排除这些扫描后计算的CR估计值。中央子野的CR为8.03 μ m（95%置信区间[CI] 7.70-8.35 μ m）。其他各亚类的CR值为6.54 ~ 18.25 μ m。来自13名受试者的扫描集具有显著的边界检测错误;排除这些受试者的再分析得出中心子场的CR为7.44 μ m，所有其他子场的CR为8 μ m，可以认为更能指示真实的临床变化，而不是测量变异性。这一发现为临床实践和临床试验设计提供了信息。（Invest Ophthalmol维斯科学。2012;53：7754-7759）DOI：10.1167/iovs.12-10895
PURPOSE. We estimated coefficients of repeatability for Spectralis optical coherence tomography (OCT)-derived automated retinal thickness and volume measurements in subjects with center-involving diabetic macular edema (DME).METHODS. A total of 50 eyes of 50 consecutive patients with center-involving DME underwent four consecutive "fast" volume scans at a single session using one OCT device operated by one of two experienced operators. Bland-Altman coefficients of repeatability (CR) were calculated for automated retinal thickness measurements in the nine Early Treatment of Diabetic Retinopathy Study (ETDRS) subfields, center point thickness, and total macular volume. Scans were evaluated for significant automated retinal boundary detection error and revised estimates for CR calculated with these scans excluded.RESULTS. CR in the central subfield was 8.03 mu m (95% confidence interval [CI] 7.70-8.35 mu m). In other subfields, CR ranged from 6.54 to 18.25 mu m. Scan sets from 13 subjects had significant boundary detection error; reanalysis with these excluded yielded a CR for the central subfield of 7.44 mu m with CR for all other subfields 8 mu m can be considered more indicative of true clinical change rather than measurement variability. This finding informs clinical practice and clinical trial design. (Invest Ophthalmol Vis Sci. 2012;53:7754-7759) DOI:10.1167/iovs.12-10895